<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297699</url>
  </required_header>
  <id_info>
    <org_study_id>GRC-TCL-2010-01</org_study_id>
    <secondary_id>2010-023841-31</secondary_id>
    <nct_id>NCT01297699</nct_id>
  </id_info>
  <brief_title>Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)</brief_title>
  <acronym>GRC</acronym>
  <official_title>Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinico Universitario de Santiago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Ramón Domínguez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinico Universitario de Santiago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to investigate tocilizumab administration in patients with moderately to&#xD;
      severely or sight-threatening GO (Graves' ophthalmopathy) without response to treatment with&#xD;
      corticoid intravenous pulses. Currently, these patients only have surgery as therapeutic&#xD;
      alternative.&#xD;
&#xD;
      The principal aim of this study is to evaluate efficacy and safety of tocilizumab treatment&#xD;
      in order to provide a better alternative to surgery for this patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid orbitopathy or Graves´orbitopathy (GO) is manifested for inflammation of the orbital&#xD;
      and periorbital soft tissues. Ten percent of patients with GO will have long-term serious eye&#xD;
      problems.&#xD;
&#xD;
      The cause of the GO is complex. Autoreactive T cells recognize an autoantigen, the TSH&#xD;
      receptor present in the orbit and thyroid follicular cell, secrete cytokines (IL-6), which&#xD;
      stimulate the fibroblasts to synthesize glycosaminoglycan, which draws liquid produce&#xD;
      periorbital edema and muscle, causing exophthalmos.&#xD;
&#xD;
      This approach suggests that inhibition of IL-6 can be an effective treatment for this problem&#xD;
      on the basis that tocilizumab specifically binds to the receptors of the IL-6, both soluble&#xD;
      and membrane-bound. Tocilizumab has been shown to inhibit signaling mediated for IL-6Rm&#xD;
      IL-6Rs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug efficacy will be established as a decrease in CAS (clinical activity score) by 2 or more points in a scale of 10.</measure>
    <time_frame>It will be measured before treatment (week -4 / 0), after treatment (week 16) and after the end of the follow-up (week 40).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response of patients who respond to treatment with tocilizumab</measure>
    <time_frame>It will be analyzed before treatment (week -4 / 0), after treatment (week 16) and once to follow up (week 40).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patients quality of life associated with tocilizumab treatment, using SF-36</measure>
    <time_frame>It will be analyzed before treatment (week -4 / 0), after treatment (week 16) and once to follow up (week 40).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine time to recurrence during follow-up period</measure>
    <time_frame>It is measured on a weeks-time scale assessed by the physician during patient follow-up visits.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as adverse events reported</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Thyroid Associated Ophthalmopathies</condition>
  <condition>Graves´ Ophthalmopathy</condition>
  <condition>Thyroid Eye Disease</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile 0.9% Sodium Chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab (RoActemra®)</intervention_name>
    <description>Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile 0.9% Sodium Chloride</intervention_name>
    <description>Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.</description>
    <arm_group_label>Sterile 0.9% Sodium Chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Principal Inclusion Criteria:&#xD;
&#xD;
        Patients diagnosed GO with CAS ≥ 4 and an index of severity, according EUGOGO guidelines,&#xD;
        1. moderately to severely or 2. sight-threatening GO, after receiving corticosteroid pulse&#xD;
        treatment due to:&#xD;
&#xD;
          -  Poor response to intravenous corticosteroid pulses Or&#xD;
&#xD;
          -  Recurrence of the GO, after treatment with intravenous corticosteroids&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Orbital decompression surgery needed immediately&#xD;
&#xD;
          -  Active smoker&#xD;
&#xD;
          -  Patients who could need treatment with radioactive iodine or thyroidectomy during the&#xD;
             study&#xD;
&#xD;
          -  Pregnant patient or patient who is planning to become pregnant during the study&#xD;
&#xD;
          -  History of chronic recurrent or active infection&#xD;
&#xD;
          -  History of intestinal ulceration or diverticulitis&#xD;
&#xD;
          -  Patients with a history of chronic liver disease or liver disorders: Alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) above 5 times upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  History of HIV, hepatitis C or hepatitis B Positive&#xD;
&#xD;
          -  Neutrophil count &lt; 0.5 × 109/L or a platelet count &lt; 50×103/μL&#xD;
&#xD;
          -  Simultaneous use or contraindications to the use of immunosuppressive agents&#xD;
&#xD;
          -  A treatment with another investigational drug within four weeks of selection or five&#xD;
             half-lives of study drug&#xD;
&#xD;
          -  Cardiovascular or cerebrovascular disease clinically significant&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Use of corticosteroids during four weeks before to inclusion period&#xD;
&#xD;
          -  History of reactions or anaphylactic allergic severe human monoclonal antibodies,&#xD;
             humanized or murine&#xD;
&#xD;
          -  Uncontrolled pathologies, whose exacerbations are treated with corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Jesús Gómez-Reino Carnota, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jóse V. Pérez Moreiras, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Oftalmológico Moreiras</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oftalmológico Moreiras</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinico Universitario de Santiago</investigator_affiliation>
    <investigator_full_name>Dr. Juan Jesus Gomez-Reino Carnota</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Graves´ orbitopathy</keyword>
  <keyword>Graves´ ophthalmopathy</keyword>
  <keyword>Thyroid eye disease</keyword>
  <keyword>Thyroid-associated ophthalmopathy</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>EUGOGO</keyword>
  <keyword>CAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

